Part of the AbGenomics Group, including AbGenomics International Inc., a clinical-stage biopharmaceutical company located in the San Francisco Bay Area.
Involved in the discovery and development of therapeutic antibodies for immune-related inflammatory diseases, allergy, asthma, transplantation rejection, and cancer.
Lead candidate AbGn-168H (Neihulizumab) has demonstrated the proof of clinical efficacy in Phase II clinical trials for T-cell mediated diseases such as psoriasis and psoriatic arthritis.
Send Message to listing owner
Listing Title: AbGenomics Corp.